Engineering Chimeric Antigen Receptors

Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells di...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulemzin, S. V., Kuznetsova, V. V., Mamonkin, M., Taranin, A. V., Gorchakov, A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A.I. Gordeyev 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406655/
https://www.ncbi.nlm.nih.gov/pubmed/28461969
_version_ 1783231996371140608
author Kulemzin, S. V.
Kuznetsova, V. V.
Mamonkin, M.
Taranin, A. V.
Gorchakov, A. A.
author_facet Kulemzin, S. V.
Kuznetsova, V. V.
Mamonkin, M.
Taranin, A. V.
Gorchakov, A. A.
author_sort Kulemzin, S. V.
collection PubMed
description Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering.
format Online
Article
Text
id pubmed-5406655
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher A.I. Gordeyev
record_format MEDLINE/PubMed
spelling pubmed-54066552017-05-01 Engineering Chimeric Antigen Receptors Kulemzin, S. V. Kuznetsova, V. V. Mamonkin, M. Taranin, A. V. Gorchakov, A. A. Acta Naturae Research Article Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens. In this review, we describe the main structural and functional elements constituting a CAR, discuss the roles of these elements in modulating the anti-tumor activity of CAR T cells, and highlight alternative approaches to CAR engineering. A.I. Gordeyev 2017 /pmc/articles/PMC5406655/ /pubmed/28461969 Text en Copyright ® 2017 Park-media Ltd. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kulemzin, S. V.
Kuznetsova, V. V.
Mamonkin, M.
Taranin, A. V.
Gorchakov, A. A.
Engineering Chimeric Antigen Receptors
title Engineering Chimeric Antigen Receptors
title_full Engineering Chimeric Antigen Receptors
title_fullStr Engineering Chimeric Antigen Receptors
title_full_unstemmed Engineering Chimeric Antigen Receptors
title_short Engineering Chimeric Antigen Receptors
title_sort engineering chimeric antigen receptors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406655/
https://www.ncbi.nlm.nih.gov/pubmed/28461969
work_keys_str_mv AT kulemzinsv engineeringchimericantigenreceptors
AT kuznetsovavv engineeringchimericantigenreceptors
AT mamonkinm engineeringchimericantigenreceptors
AT taraninav engineeringchimericantigenreceptors
AT gorchakovaa engineeringchimericantigenreceptors

Ejemplares similares